<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04912752</url>
  </required_header>
  <id_info>
    <org_study_id>2020/12</org_study_id>
    <nct_id>NCT04912752</nct_id>
  </id_info>
  <brief_title>Copy Number Variation in CHRNA7 Gene in Migraine and Gene Expression</brief_title>
  <official_title>Copy Number Variation in Migraine and Gene Expression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Gaziantep</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Gaziantep</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Migraine is a common and possible hereditary disease. Copy number variation (CNV) is a&#xD;
      phenomenon in which parts of the genome are repeated and the number of repeats in the genome&#xD;
      varies between individuals in the human population.The CHRNA7 gene has a major role in the&#xD;
      neuropsychiatric phenotypes observed in patients. The 15q13.3 gain/loss variation in this&#xD;
      gene may be associated with migraine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Migraine is a common neurological disorder. Although they have different genetic bases&#xD;
      according to their types, cholinergic receptors after calcium channels play an important role&#xD;
      in the clinic and genetics of the disease. Neuronal acetylcholine receptor subunit alpha-7,&#xD;
      also known as nAChRα7, is a protein that in humans is encoded by the CHRNA7 gene.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 5, 2020</start_date>
  <completion_date type="Actual">January 2, 2021</completion_date>
  <primary_completion_date type="Actual">December 10, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CNV number</measure>
    <time_frame>1 year</time_frame>
    <description>CNV number effect on migraine</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Case-Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Copy number variation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Case-Control 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gene expression</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Migraine CNV</intervention_name>
    <description>Copy number variation effect on migraine disease</description>
    <arm_group_label>Case-Control</arm_group_label>
    <arm_group_label>Case-Control 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Migraine&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Vascular problems&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mehmet Fatih Özaltun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assist</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medicine</name>
      <address>
        <city>Gaziantep</city>
        <state>Şehitkamil</state>
        <zip>27310</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 21, 2021</study_first_submitted>
  <study_first_submitted_qc>May 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2021</study_first_posted>
  <last_update_submitted>May 31, 2021</last_update_submitted>
  <last_update_submitted_qc>May 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Gaziantep</investigator_affiliation>
    <investigator_full_name>Şenay Görücü Yılmaz</investigator_full_name>
    <investigator_title>Assoc. Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>manuscript not yet published</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

